You are here: Home / IOF research managers

IOF research managers

Nick Geukens (PhD) is a biochemist by training. He obtained his PhD in Biochemistry studying the role of signal peptidases in Gram-positive bacteria in the group of Prof. J. Anné at the Rega Institute for Medical Research (KU Leuven). He stayed as post-doc in the same group focusing on rational design of novel antibacterials targeting protein secretion pathway components. Since 2008, he started as coordinator of PharmAbs, the KU Leuven Antibody Center (www.pharmabs.org). Since 2009, he is an IOF research manager of the KU Leuven. PharmAbs clusters the antibody technologies from 5 KU Leuven laboratories and supports academic groups in the development of novel antibody-based therapeutic lead products and the design, development and validation of immunoassays. PharmAbs also provides customized antibodies to the research community.


Frauke Christ (PhD) was trained as a biologist at the Justus-Liebig University in Giessen (Germany) where she received her PhD in Biochemistry studying the enzymology of homing endonucleases. Following her PhD training she joined the group of Prof. Greg Verdine at the Chemistry and Chemical Biology department (Harvard University, USA) as a post-doc focusing her work on recombination specific nucleases. Subsequently she became a postdoctoral-fellow in the lab of Molecular Virology and Gene Therapy (MolVirGen, Prof. Zeger Debyser) developing a validation pathway for novel drug targets. Since 2007 she is an IOF fellow focusing her research on drug discovery in HIV and cancer (http://www.kuleuven.be/molmed/cellcovir/index.html). The drug discovery platform at MolvirGen is specialized in protein-protein interactions including target validation, assay development and compound profiling techniques and is open for third parties through collaboration or fee-for-service research.


Annelii Ny (PhD) trained as a biochemist and received her PhD in Medicinal Biochemistry and Biophysics from University of Umeå (Sweden) on protease involvement in extracellular matrix degradation. After postdoctoral positions at the Dept. of Venerology and Dermatology (Umeå University) and the Vesalius Research Center (VIB/KU Leuven) she joined the Laboratory for Molecular Biodiscovery (LMB), (Prof. Peter de Witte, KU Leuven) in 2012 to develop organ specific transgenic zebrafish and disease models. In 2016 she was appointed as IOF Manager in the same research group. The LMB uses a zebrafish technology platform to perform drug discovery and safety assessment of compounds and is open to third parties via collaboration or fee-for-service research.